<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467999</url>
  </required_header>
  <id_info>
    <org_study_id>#6393</org_study_id>
    <secondary_id>6393</secondary_id>
    <nct_id>NCT01467999</nct_id>
  </id_info>
  <brief_title>Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence</brief_title>
  <acronym>GUAN</acronym>
  <official_title>Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether guanfacine represents a tolerable,
      potentially effective pharmacotherapy option for cannabis dependence. Interested in seeing
      whether guanfacine treatment reduces marijuana consumption, withdrawal symptoms, and craving
      as compared to baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cannabis use disorders remain the most common illicit drug use disorder and options for
      treatment remain limited. Compared to other abusable substances, there has been little
      investigation of pharmacotherapies for cannabis dependence and no effective pharmacotherapy
      for cannabis dependence has been developed yet. As such, the development of effective
      cannabis dependence pharmacotherapy is an important unmet public health need. Lofexidine, an
      alpha-2 agonist, is effective in treating opioid withdrawal and shows promise as cannabis use
      disorder pharmacotherapy, though its use may be limited by a cumbersome (thrice daily) dosing
      regimen. An alpha-2-agonist with a longer half-life, such as guanfacine, may have some of the
      same benefits as lofexidine at comparable doses, but its easier (once daily) dosing regimen
      may promote compliance and treatment retention. The purpose of this study is therefore to
      determine whether guanfacine represents a tolerable, potentially effective pharmacotherapy
      option for cannabis dependence. This pilot study can also provide the basis for subsequently
      conducting a larger study aimed at determining efficacy with the appropriate randomized,
      placebo-controlled design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Mean Number of Days of Cannabis Use Per Week</measure>
    <time_frame>Daily cannabis use reported during the 8 week trial or the length of the patient's participation</time_frame>
    <description>The reduction in cannabis consumption quantified by the number of days of cannabis use per week was assessed, as measured by the Time Line followback, reported week 1 compared to week 8.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Cannabis Dependence</condition>
  <arm_group>
    <arm_group_label>Guanfacine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guanfacine, 4mg given once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine</intervention_name>
    <description>Guanfacine, 4mg given once daily</description>
    <arm_group_label>Guanfacine</arm_group_label>
    <other_name>Intuniv</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between the ages of 18-60 who meet DSM-IV criteria for current marijuana
             dependence

          -  Individuals must report using marijuana at least 20 days in the past 30 days and have
             a positive urine test for THC on the day of study entry.

          -  Individual must describe marijuana as their primary drug of abuse.

          -  Individuals must be capable of giving informed consent and capable of complying with
             study procedures.

        Exclusion Criteria:

          -  Meets DSM-IV-TR criteria for schizophrenia, schizoaffective illness, psychotic
             disorder other than transient psychosis due to drug abuse, major depression, bipolar
             illness or psychiatric disorders (other than substance abuse) which require
             psychiatric intervention.

          -  Unstable medication conditions, such as poorly controlled diabetes or hypertension
             (&gt;140/90 mmHg), which might make participation hazardous.

          -  Individuals with liver enzyme function tests greater than three times normal, or acute
             hepatitis

          -  Individuals with a history of a seizure disorder

          -  Individuals with current suicidal risk.

          -  Individuals who are cognitively impaired

          -  Bradycardia (&lt; 50 beats/minute), hypotension (sitting or standing BP &lt; 90/50), or
             symptoms attributable to low BP (i.e. lightheadedness or dizziness on standing).

          -  Nursing mothers and pregnant women. Women of child bearing age will be included in the
             study provided that they are not pregnant, based on the results of a blood pregnancy
             test drawn at the time of screening. They must also agree to use a method of
             contraception with proven efficacy and agree not to become pregnant during the study.
             To confirm this, urine pregnancy tests will be repeated monthly. Women will be
             provided a full explanation of the potential dangers of pregnancy while on the study
             medication. If a woman becomes pregnant, the study medication will be discontinued.

          -  Individuals who are physiologically dependent on any other drugs (excluding nicotine)
             that would require a medical intervention

          -  Individuals with known sensitivity to alpha-2 Agonists

          -  Individuals with coronary vascular disease as indicated by history or suspected by
             abnormal ECG or history of cardiac symptoms

          -  Individuals currently being treated with antihypertensive medication, including
             alpha-2 agonists

          -  Individuals currently taking medications that may interact adversely with guanfacine.

          -  Individuals who are court-mandated to treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances Levin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elias Dakwar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>STARS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <results_first_submitted>May 16, 2018</results_first_submitted>
  <results_first_submitted_qc>May 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2018</results_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Frances R Levin</investigator_full_name>
    <investigator_title>Director of Substance Use Disorder</investigator_title>
  </responsible_party>
  <keyword>cannabis dependence</keyword>
  <keyword>marijuana dependence</keyword>
  <keyword>guanfacine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants responded to newspapers, radio and public service announcements in the New York City area, and reported at least 20 days of use in the past 30 days.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Guanfacine</title>
          <description>Guanfacine, 4mg given once daily
Guanfacine: Guanfacine, 4mg given once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Guanfacine</title>
          <description>Guanfacine, 4mg given once daily
Guanfacine: Guanfacine, 4mg given once daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Mean Number of Days of Cannabis Use Per Week</title>
        <description>The reduction in cannabis consumption quantified by the number of days of cannabis use per week was assessed, as measured by the Time Line followback, reported week 1 compared to week 8.</description>
        <time_frame>Daily cannabis use reported during the 8 week trial or the length of the patient's participation</time_frame>
        <population>intent-to-treat sample</population>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine</title>
            <description>Guanfacine, 4mg given once daily
Guanfacine: Guanfacine, 4mg given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Mean Number of Days of Cannabis Use Per Week</title>
          <description>The reduction in cannabis consumption quantified by the number of days of cannabis use per week was assessed, as measured by the Time Line followback, reported week 1 compared to week 8.</description>
          <population>intent-to-treat sample</population>
          <units>days of use per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during 8 weeks of open label participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Guanfacine</title>
          <description>Guanfacine, 4mg given once daily
Guanfacine: Guanfacine, 4mg given once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>increased urination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>lightheadedness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to its open-label nature, it is not possible to determine whether the reductions in cannabis use were due to study drug, or whether they were related to other study procedures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>daniel brooks</name_or_title>
      <organization>NYSPI</organization>
      <phone>6467746171</phone>
      <email>daniel.brooks@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

